View Past PerformanceThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsApplied Genetic Technologies 대차대조표 건전성재무 건전성 기준 점검 3/6핵심 정보92.62%부채/자본 비율US$16.34m부채이자보상배율n/a현금US$34.24m자본US$17.65m총부채US$39.69m총자산US$57.33m최근 재무 건전성 업데이트분석 기사 • May 21Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Jan 06Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...모든 업데이트 보기Recent updatesBoard Change • Oct 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Price Target Changed • Sep 30Price target decreased to US$8.00Down from US$10.00, the current price target is an average from 5 analysts. New target price is 2,846% above last closing price of US$0.27. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.07 next year compared to a net loss per share of US$1.53 last year.Seeking Alpha • Jul 26AGTC receives positive feedback from FDA for manufacturing facilityApplied Genetic Technologies (NASDAQ:AGTC) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, including the late-stage development and potential commercialization of its eye diseases therapy like X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs. The company said initial operations at the facility are expected to begin in Q4 with GMP capabilities expected to be finalized in Q1 2023. "We expect the facility will also play an important role in support of our promising pipeline of additional clinical and pre-clinical programs," the company said. (AGTC) rose 1.3% premarket.Seeking Alpha • Jul 12Applied Genetic Technologies proposes stock offering to fund clinical trialsApplied Genetic Technologies (NASDAQ:AGTC) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa program and its ongoing Phase 1/2 clinical trials in its Achromatopsia program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. AGTC Shares fell 29% after-hours, Tuesday, to trade at $0.60. Earlier: Applied Genetic Technologies raised $9.8M in stock offeringPrice Target Changed • Jun 10Price target decreased to US$10.57Down from US$14.63, the current price target is an average from 7 analysts. New target price is 1,037% above last closing price of US$0.93. Stock is down 78% over the past year. The company is forecast to post a net loss per share of US$1.47 next year compared to a net loss per share of US$1.77 last year.Price Target Changed • May 17Price target decreased to US$14.13Down from US$15.63, the current price target is an average from 7 analysts. New target price is 1,586% above last closing price of US$0.84. Stock is down 81% over the past year. The company is forecast to post a net loss per share of US$1.66 next year compared to a net loss per share of US$1.77 last year.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Seeking Alpha • Jan 12Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022AGTC-501 is being developed to treat patients with X-linked retinitis pigmentosa. Two near-term results are expected in Q2 and Q3 of 2022, respectively; they are 3-month results from the SKYLINE study and 24-month results from the phase 1/2 study using AGTC-501. Results from two phase 1/2 studies pediatric patients with Achromatopsia are expected in Q1 of 2022. Applied Genetic Technologies Corporation had $90.5 million cash as of September 30, 2021; enough cash to fund its operations into 2023.Seeking Alpha • Dec 14An Assessment Of Applied Genetic Technologies CorporationIn the spotlight today is a developmental concern called Applied Genetic Technologies Corporation. The company has several gene therapy candidates in its pipeline and numerous potential milestones in 2022. A full investment analysis is provided in the paragraphs below.Board Change • Nov 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Oct 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Seeking Alpha • Jul 15Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased RiskApplied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases. AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linked retinitis pigmentosa, achromatopsia, and optogenetics. AGT Corporation is in a reasonable financial position evidenced by 2+ years of cash runway driven by a low-cash burn (TTM: -$53M) and cash of $111M (March 2021). XLRP is being targeted by AGTC's lead therapeutic, RPGR, currently in a Phase 2/3 Vista study (data expected: 3Q 22) and a Phase 1/2 expansion trial known as Skyline (data expected: 4Q 21). In summary, the author projects Applied Genetic Technologies Corporation as a high-risk "hold".분석 기사 • May 21Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyst Estimate Surprise Post Earnings • Feb 12Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.0%.분석 기사 • Feb 05What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?Every investor in Applied Genetic Technologies Corporation ( NASDAQ:AGTC ) should be aware of the most powerful...Price Target Changed • Feb 02Price target lowered to US$11.44Down from US$14.81, the current price target is an average from 6 analysts. The new target price is 190% above the current share price of US$3.95. As of last close, the stock is down 35% over the past year.Is New 90 Day High Low • Jan 29New 90-day low: US$3.95The company is down 23% from its price of US$5.16 on 30 October 2020. The American market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 24% over the same period.분석 기사 • Jan 06Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Dec 11What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...Is New 90 Day High Low • Nov 18New 90-day low: US$4.33The company is down 21% from its price of US$5.51 on 20 August 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 18Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 13%. Over the next year, revenue is expected to shrink by 88% compared to a 365% growth forecast for the Biotechs industry in the US.Reported Earnings • Sep 21Full year earnings released - US$2.17 loss per shareOver the last 12 months the company has reported total losses of US$45.9m, with losses widening by US$43.7m from the prior year.재무 상태 분석단기부채: AGTC 의 단기 자산 ( $37.2M )이 단기 부채( $26.6M ).장기 부채: AGTC의 단기 자산($37.2M)이 장기 부채($13.1M)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: AGTC 총 부채보다 더 많은 현금을 보유하고 있습니다.부채 감소: 지난 5년 동안 AGTC의 부채 대비 자본 비율이 감소했는지 판단하기에 데이터가 부족합니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: AGTC 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.예측 현금 활주로: 무료 현금 흐름이 매년 15.4 %의 역사적 비율로 계속 감소할 경우 AGTC 의 현금 활주로는 1년 미만입니다.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/12/01 20:07종가2022/11/30 00:00수익2022/09/30연간 수익2022/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Applied Genetic Technologies Corporation는 10명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관James BirchenoughBMO Capital Markets Equity ResearchYun ZhongBrean Capital Historical (Janney Montgomery)Yun ZhongBTIG7명의 분석가 더 보기
분석 기사 • May 21Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Jan 06Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Board Change • Oct 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Price Target Changed • Sep 30Price target decreased to US$8.00Down from US$10.00, the current price target is an average from 5 analysts. New target price is 2,846% above last closing price of US$0.27. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.07 next year compared to a net loss per share of US$1.53 last year.
Seeking Alpha • Jul 26AGTC receives positive feedback from FDA for manufacturing facilityApplied Genetic Technologies (NASDAQ:AGTC) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, including the late-stage development and potential commercialization of its eye diseases therapy like X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs. The company said initial operations at the facility are expected to begin in Q4 with GMP capabilities expected to be finalized in Q1 2023. "We expect the facility will also play an important role in support of our promising pipeline of additional clinical and pre-clinical programs," the company said. (AGTC) rose 1.3% premarket.
Seeking Alpha • Jul 12Applied Genetic Technologies proposes stock offering to fund clinical trialsApplied Genetic Technologies (NASDAQ:AGTC) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa program and its ongoing Phase 1/2 clinical trials in its Achromatopsia program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. AGTC Shares fell 29% after-hours, Tuesday, to trade at $0.60. Earlier: Applied Genetic Technologies raised $9.8M in stock offering
Price Target Changed • Jun 10Price target decreased to US$10.57Down from US$14.63, the current price target is an average from 7 analysts. New target price is 1,037% above last closing price of US$0.93. Stock is down 78% over the past year. The company is forecast to post a net loss per share of US$1.47 next year compared to a net loss per share of US$1.77 last year.
Price Target Changed • May 17Price target decreased to US$14.13Down from US$15.63, the current price target is an average from 7 analysts. New target price is 1,586% above last closing price of US$0.84. Stock is down 81% over the past year. The company is forecast to post a net loss per share of US$1.66 next year compared to a net loss per share of US$1.77 last year.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Seeking Alpha • Jan 12Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022AGTC-501 is being developed to treat patients with X-linked retinitis pigmentosa. Two near-term results are expected in Q2 and Q3 of 2022, respectively; they are 3-month results from the SKYLINE study and 24-month results from the phase 1/2 study using AGTC-501. Results from two phase 1/2 studies pediatric patients with Achromatopsia are expected in Q1 of 2022. Applied Genetic Technologies Corporation had $90.5 million cash as of September 30, 2021; enough cash to fund its operations into 2023.
Seeking Alpha • Dec 14An Assessment Of Applied Genetic Technologies CorporationIn the spotlight today is a developmental concern called Applied Genetic Technologies Corporation. The company has several gene therapy candidates in its pipeline and numerous potential milestones in 2022. A full investment analysis is provided in the paragraphs below.
Board Change • Nov 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Oct 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Bill Aliski was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Seeking Alpha • Jul 15Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased RiskApplied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases. AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linked retinitis pigmentosa, achromatopsia, and optogenetics. AGT Corporation is in a reasonable financial position evidenced by 2+ years of cash runway driven by a low-cash burn (TTM: -$53M) and cash of $111M (March 2021). XLRP is being targeted by AGTC's lead therapeutic, RPGR, currently in a Phase 2/3 Vista study (data expected: 3Q 22) and a Phase 1/2 expansion trial known as Skyline (data expected: 4Q 21). In summary, the author projects Applied Genetic Technologies Corporation as a high-risk "hold".
분석 기사 • May 21Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analyst Estimate Surprise Post Earnings • Feb 12Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.0%.
분석 기사 • Feb 05What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?Every investor in Applied Genetic Technologies Corporation ( NASDAQ:AGTC ) should be aware of the most powerful...
Price Target Changed • Feb 02Price target lowered to US$11.44Down from US$14.81, the current price target is an average from 6 analysts. The new target price is 190% above the current share price of US$3.95. As of last close, the stock is down 35% over the past year.
Is New 90 Day High Low • Jan 29New 90-day low: US$3.95The company is down 23% from its price of US$5.16 on 30 October 2020. The American market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 24% over the same period.
분석 기사 • Jan 06Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Dec 11What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...
Is New 90 Day High Low • Nov 18New 90-day low: US$4.33The company is down 21% from its price of US$5.51 on 20 August 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 18Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 13%. Over the next year, revenue is expected to shrink by 88% compared to a 365% growth forecast for the Biotechs industry in the US.
Reported Earnings • Sep 21Full year earnings released - US$2.17 loss per shareOver the last 12 months the company has reported total losses of US$45.9m, with losses widening by US$43.7m from the prior year.